GSA Capital Partners LLP lifted its holdings in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH – Free Report) (TSE:AUP) by 1,051.0% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 131,948 shares of the biotechnology company’s stock after buying an additional 120,484 shares during the period. GSA Capital Partners LLP’s holdings in Aurinia Pharmaceuticals were worth $2,105,000 at the end of the most recent reporting period.
Other hedge funds have also recently made changes to their positions in the company. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Aurinia Pharmaceuticals during the 3rd quarter valued at about $48,000. State of Alaska Department of Revenue purchased a new stake in shares of Aurinia Pharmaceuticals during the 3rd quarter valued at about $91,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Aurinia Pharmaceuticals by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,407 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 1,318 shares in the last quarter. BNP Paribas Financial Markets raised its position in shares of Aurinia Pharmaceuticals by 32.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 13,034 shares of the biotechnology company’s stock valued at $110,000 after buying an additional 3,191 shares in the last quarter. Finally, CIBC Bancorp USA Inc. purchased a new stake in Aurinia Pharmaceuticals in the 3rd quarter worth about $137,000. 36.83% of the stock is currently owned by hedge funds and other institutional investors.
Aurinia Pharmaceuticals Stock Performance
Shares of NASDAQ:AUPH opened at $15.55 on Wednesday. The firm has a market cap of $2.00 billion, a PE ratio of 7.17 and a beta of 1.44. The firm’s 50 day simple moving average is $15.33 and its 200-day simple moving average is $15.17. Aurinia Pharmaceuticals Inc has a one year low of $7.28 and a one year high of $16.88. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.01 and a current ratio of 5.55.
Insider Activity
In other Aurinia Pharmaceuticals news, Director Kevin Tang acquired 516,439 shares of the company’s stock in a transaction dated Friday, February 27th. The shares were purchased at an average cost of $13.99 per share, for a total transaction of $7,224,981.61. Following the completion of the purchase, the director owned 11,845,939 shares in the company, valued at approximately $165,724,686.61. This trade represents a 4.56% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 12.20% of the company’s stock.
Analyst Ratings Changes
Separately, Weiss Ratings lowered shares of Aurinia Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday. Two equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $17.25.
Check Out Our Latest Stock Report on AUPH
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.
The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.
Featured Articles
- Five stocks we like better than Aurinia Pharmaceuticals
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
- Brady Corp Wires Up a Massive AI-Powered Breakout
- Why Home Depot’s Sell-Off Could Become a Huge Opportunity
Want to see what other hedge funds are holding AUPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aurinia Pharmaceuticals Inc (NASDAQ:AUPH – Free Report) (TSE:AUP).
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
